All In Biotech

Drug Trial Radar · NCT07509151

Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)

A Phase III, Randomised, Open-label, Multicentre, Study of Surovatamig as Consolidation Therapy Versus Observation After First-line Induction Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV (SOUNDTRACK-C1)

Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 420 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

420

Planned (sponsor's estimate)

Start

May 5, 2026

Primary completion

Aug 29, 2031

Study completion Apr 5, 2032

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Parexel
First posted
Apr 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the therapeutic benefit and safety of subcutaneous (SC) Surovatamig monotherapy as consolidation therapy in patients with Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) with unmutated IGHV (uIGHV).

Conditions

  • Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV

Interventions

  • SurovatamigDrug

    Surovatamig will be administered as a subcutaneous injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DOSRI- Number of participants with adverse events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to 5 years
  2. Phase III- Progression Free Survival (PFS)Time frame: Until disease progression or death (up to 5 years)
  3. DOSRI- Number of participants with study intervention discontinuations, dose reductions and dose delays due to AEsTime frame: Up to 5 years

Locations

44 sites in 5 countries. Site status is shown where the registry gives one.

  • Research Site

    La Jolla, California · Not yet recruiting

  • Research Site

    Denver, Colorado · Not yet recruiting

  • Research Site

    New Haven, Connecticut · Not yet recruiting

  • Research Site

    Chicago, Illinois · Not yet recruiting

  • Research Site

    Kansas City, Kansas · Not yet recruiting

  • Research Site

    Louisville, Kentucky · Not yet recruiting

  • Research Site

    Bethesda, Maryland · Not yet recruiting

  • Research Site

    Boston, Massachusetts · Not yet recruiting

  • Research Site

    Rochester, Minnesota · Not yet recruiting

  • Research Site

    Basking Ridge, New Jersey · Not yet recruiting

  • Research Site

    Rochester, New York · Not yet recruiting

  • Research Site

    Cleveland, Ohio · Not yet recruiting

  • Research Site

    Pittsburgh, Pennsylvania · Not yet recruiting

  • Research Site

    Houston, Texas · Not yet recruiting

  • Research Site

    Adelaide, Australia · Recruiting

  • Research Site

    Fitzroy, Australia · Not yet recruiting

  • Research Site

    Heidelberg, Australia · Recruiting

  • Research Site

    Nedlands, Australia · Recruiting

  • Research Site

    Perth, Australia · Recruiting

  • Research Site

    Rockingham, Australia · Not yet recruiting

  • Research Site

    Calgary, Alberta, Canada · Recruiting

  • Research Site

    Vancouver, British Columbia, Canada · Suspended

  • Research Site

    Halifax, Nova Scotia, Canada · Recruiting

  • Research Site

    Hamilton, Ontario, Canada · Not yet recruiting

  • Research Site

    Toronto, Ontario, Canada · Recruiting

  • Research Site

    Montreal, Quebec, Canada · Suspended

  • Research Site

    Montreal, Quebec, Canada · Recruiting

  • Research Site

    Québec, Quebec, Canada · Suspended

  • Research Site

    Adapazarı, Turkey (Türkiye) · Recruiting

  • Research Site

    Antalya, Turkey (Türkiye) · Recruiting

  • Research Site

    Istanbul, Turkey (Türkiye) · Not yet recruiting

  • Research Site

    Istanbul, Turkey (Türkiye) · Recruiting

  • Research Site

    Istanbul, Turkey (Türkiye) · Recruiting

  • Research Site

    Kocaeli, Turkey (Türkiye) · Recruiting

  • Research Site

    Mezitli, Turkey (Türkiye) · Recruiting

  • Research Site

    Edinburgh, United Kingdom · Recruiting

  • Research Site

    Hampshire, United Kingdom · Recruiting

  • Research Site

    Leeds, United Kingdom · Not yet recruiting

  • Research Site

    London, United Kingdom · Recruiting

  • Research Site

    London, United Kingdom · Recruiting

Showing 40 of 44 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.